299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05239611 (ClinicalTrials.gov) | February 14, 2022 | 10/1/2022 | Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis | Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis to Improve Patient-centered Outcomes, Including a Novel Measure of Ventilation | Cystic Fibrosis | Drug: Exercise | University of Kansas Medical Center | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |
| 2 | NCT04039087 (ClinicalTrials.gov) | September 5, 2019 | 28/7/2019 | Sildenafil Exercise: Role of PDE5 Inhibition | Mechanisms of Exercise Intolerance in Cystic Fibrosis: Role of PDE5 Inhibition | Cystic Fibrosis | Drug: Sildenafil 40mg oral capsule;Drug: Placebo Oral capsule | National Jewish Health | Augusta University;Cystic Fibrosis Foundation | Recruiting | 9 Years | N/A | All | 40 | Phase 2/Phase 3 | United States |
| 3 | NCT03522831 (ClinicalTrials.gov) | May 1, 2018 | 19/3/2018 | CF Bronchodilation | A Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic Fibrosis | Lung Diseases;Cystic Fibrosis | Drug: Salbutamol;Drug: Placebo | University of British Columbia | NULL | Active, not recruiting | 19 Years | N/A | All | 20 | N/A | Canada |
| 4 | NCT02875366 (ClinicalTrials.gov) | September 2016 | 15/8/2016 | A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation | A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | Cystic Fibrosis | Drug: LUM/IVA;Drug: Placebo | Vertex Pharmaceuticals Incorporated | NULL | Completed | 12 Years | N/A | All | 70 | Phase 4 | Australia;United Kingdom |
| 5 | EUCTR2016-000066-34-GB (EUCTR) | 24/06/2016 | 25/07/2017 | A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation. | Cystic fibrosis in patients homozygous for the F508del-CFTR Mutation MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Orkambi Product Name: lumacaftor/ivacaftor Product Code: VX-809/VX-770 INN or Proposed INN: lumacaftor Other descriptive name: LUMACAFTOR INN or Proposed INN: IVACAFTOR | Vertex Pharmaceuticals Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 66 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | Australia;United Kingdom | ||
| 6 | NCT02057458 (ClinicalTrials.gov) | April 2014 | 4/2/2014 | Blood Flow and Vascular Function in Cystic Fibrosis | Role of Blood Flow and Vascular Function on Exercise Capacity in Cystic Fibrosis | Cystic Fibrosis | Drug: Sildenafil (Acute-1 hour);Drug: Sildenafil (Subchronic-4 weeks);Drug: Placebo | Augusta University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 18 Years | N/A | All | 19 | Phase 2 | United States |
| 7 | NCT01937325 (ClinicalTrials.gov) | February 2014 | 4/9/2013 | CPET in CF Patients With One G551D Mutation Taking VX770 | Airway Infection, Inflammatory Markers and Exercise Capacity in Patients With Cystic Fibrosis and at Least One G551D Mutation Taking VX770 (Ivacaftor) | Cystic Fibrosis | Drug: ivacaftor;Drug: placebo | The Alfred | NULL | Active, not recruiting | 16 Years | 70 Years | Both | 20 | Phase 4 | Australia |
| 8 | NCT01772758 (ClinicalTrials.gov) | August 2011 | 16/10/2012 | Cystic Fibrosis and Endothelial Function: At Rest and During Exercise | Influence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During Exercise | Cystic Fibrosis | Drug: BH4 5mg;Drug: BH4 20mg;Dietary Supplement: Antioxidant Cocktail | Augusta University | NULL | Completed | 7 Years | N/A | All | 64 | Phase 2 | United States |
| 9 | NCT00434278 (ClinicalTrials.gov) | March 2007 | 11/2/2007 | A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease | Cystic Fibrosis | Drug: Dornase alfa;Drug: placebo | Genentech, Inc. | NULL | Terminated | 14 Years | N/A | All | 27 | Phase 4 | United States |
| 10 | NCT00164021 (ClinicalTrials.gov) | February 2001 | 13/9/2005 | The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation | The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function | Cystic Fibrosis | Procedure: Physiotherapy, exercise, percutaneous gastrostomy feeds;Drug: Anti-reflux pharmacotherapy | Bayside Health | The Alfred;Monash University | Recruiting | 16 Years | 70 Years | Both | 180 | N/A | Australia |